Project TitleA Function Blocking Monoclonal Antibody Against alpha4 Laminin
Track Code1999-053
Short Description

Researchers at Northwestern University have developed a function blocking monoclonal antibody (mAb) to thea4 subunit of laminin.

#therapeutics #cancer #antibody #researchtool


This antibody, mAb 2A3, inhibits angiogenesis and endothelializationin vitro and in vivo.  Integrins are cellular receptors that mediate cell-cell and cell-extracellular matrix interactions, and integrin avß3 is postulated to play a major role in angiogenesis by acting as a receptor fora subunits and modulating a variety of cell-cell interactions. Thea4 subunit is a ligand for theavß3 integrin, and the 2A3 antibody acts to blocka4 subunit interactions withavß3

In vivo matrigel assays have demonstrated that the 2A3 antibody can inhibit angiogenesis. Experiments have demonstrated that the 2A3 antibody is able to inhibitin vitro wound healing of endothelial cells. Currently, an antibody toavß3 integrin (Vitaxin) is being evaluated in clinical trials. However, data obtained by our investigators indicate that the 2A3 antibody developed at Northwestern is more efficient than Vitaxin at blocking two essential aspects of angiogenesis: branching morphogenesis and migration of endothelial cells.

TagsTHERAPEUTICS: antibody, THERAPEUTICS: cancer, research tool: antibody
Posted DateMar 21, 2011 6:08 PM


Meredith Gonzales
Jonathan Jones* 



Northwestern is interested in licensing the technology for commercialization. Further non-confidential information is available upon request and information regarding the 2A3 antibody can be found in the published papers listed above.

Contact Information

Gwendolyn Humphreys, PhD 
Invention Associate

(p) 847-467-0308